Email Alert | RSS

北京大学学报（医学版） ›› 2021, Vol. 53 ›› Issue (4): 647-652. doi: 10.19723/j.issn.1671-167X.2021.04.004

• 论著 • 上一篇    下一篇

术前血小板参数与局部进展期肾细胞癌预后

肖若陶,刘承,徐楚潇,何为,马潞林()   

  1. 北京大学第三医院泌尿外科,北京 100191
  • 收稿日期:2021-03-10 出版日期:2021-08-18 发布日期:2021-08-25
  • 通讯作者: 马潞林 E-mail:malulin@bjmu.edu.cn
  • 基金资助:
    国家自然科学基金(81972381)

Prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma

XIAO Ruo-tao,LIU Cheng,XU Chu-xiao,HE Wei,MA Lu-lin()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2021-03-10 Online:2021-08-18 Published:2021-08-25
  • Contact: Lu-lin MA E-mail:malulin@bjmu.edu.cn
  • Supported by:
    National Natural Science Foundation of China(81972381)

RICH HTML

 21   

PDF (PC)

229

摘要：

目的: 探讨术前血小板参数对局部进展期肾癌预后的预测价值,为此类患者的危险分层提供参考。方法: 选择北京大学第三医院2015年1月—2017年12月局部进展期肾癌患者进行回顾性分析,依据随访过程中肿瘤是否复发或转移分成进展组和无进展组,比较两组术前血小板参数和临床资料的差异。通过受试者特征工作曲线(receiver operating characteristic curve, ROC)确定血小板参数的最佳临界值,Kaplan-Meier生存曲线分析不同血小板参数与疾病无进展生存时间(progression-free survival, PFS)的关系。通过Cox比例风险模型进行多因素分析确定PFS的独立危险因素。采用时间依赖ROC、净重新分类指数(net reclassification index, NRI)和综合判别改善指数(integrated discrimination improvement, IDI)评估纳入血小板参数后对SSIGN模型改良情况。结果: 共有215例患者入选本研究,其中192例(89.3%)患者获得随访,中位随访时间为36个月。64例(29.8%)患者随访过程中出现疾病进展,中位PFS为46个月。进展组患者的血小板数量(platelet count, PLT)相较无进展组高[(250.72±88.59)×109/L vs. (227.27±66.94)×109/L, P=0.042],血小板分布宽度(platelet distribution width, PDW)相较无进展组低[(12.01±2.27)% vs. (13.31±2.74)%, P=0.001]。将285×109/L及12.65%作为PLT及PDW的最佳临界值,PLT≤285×109/L组患者中位PFS显著长于PLT>285×109/L组(53个月vs. 41个月,P=0.033);PDW>12.65%组患者中位PFS也显著长于PDW≤12.65%组(56个月vs. 41个月,P<0.001)。多因素分析显示术前PDW(HR=0.735, P<0.001)、细胞核分级Ⅲ~Ⅳ级(HR=2.425, P=0.001)、合并肉瘤样分化(HR=3.101, P=0.008)为PFS的独立危险因素。术前PDW联合SSIGN预后评分模型曲线下面积大于原有SSIGN模型[0.748 (95%CI:0.662~0.833) vs. 0.678 (95%CI: 0.583~0.773), P=0.193],NRI为0.262(P=0.04),IDI为 0.085(P=0.01),表明PDW纳入SSIGN模型后其预测能力提高。结论: 术前高PLT和低PDW与局部进展期肾癌不良预后相关,其中PDW是患者预后的独立危险因素,因此,术前PDW有助于对局部进展期肾癌进行危险分层。

关键词: 肾癌, 局部进展期, 血小板, 预后

Abstract:

Objective: To explore the prognostic value of preoperative platelet parameters in locally advanced renal cell carcinoma for the risk stratification of such patients. Methods: Clinical data of patients with locally advanced renal cell carcinoma in the Third Hospital of Peking University from January 2015 to December 2017 were collected. The patients were divided into progression group and progression-free group according to follow-up data, and preoperative platelet parameters and clinical data between the two groups were compared. The optimal cut-off value of platelet parameters was determined by receiver operating characteristic curve (ROC) and analyzed by Kaplan-Meier survival curve. Cox proportional hazards model was used to analyze the independent risk factors of PFS. Time dependent ROC curve, net reclassification index (NRI), and integrated discrimination improvement (IDI) were used to evaluate the improvement of SSIGN model by incorporating platelet parameters. Results: Of the 215 patients, 192 (89.3%) were followed up for a median of 36 months. Sixty-four patients (29.8%) had disease progression during the follow-up, and the median PFS was 46 months. In progression group, the platelet count (PLT) was higher [(250.72 ± 88.59)×109/L vs. (227.27 ± 66.94)×109/L, P=0.042] and the platelet distribution width (PDW) was lower [(12.01 ± 2.27)% vs. (13.31 ± 2.74)%, P = 0.001] than that of progression-free groups. 285×109 /L and 12.65% as the best cut-off values of PLT and PDW, the median PFS of PLT≤285×109 /L group was significantly longer than that of PLT>285×109 /L group (53 months vs. 41 months, P=0.033), and the median PFS of PDW>12.65% group was also significantly longer than that of PDW≤12.65% group (56 months vs. 41 months, P<0.001). Multivariate analysis showed that preoperative PDW (HR=0.735, P<0.001), nuclear grade Ⅲ to Ⅳ (HR=2.425, P=0.001) and sarcomatoid differentiation (HR=3.101, P=0.008) were independent risk factors for PFS. The area under the curve of PDW combined with SSIGN model was larger than that with the original SSIGN model [0.748 (95%CI:0.662-0.833) vs. 0.678 (95%CI: 0.583-0.773), P=0.193], NRI was 0.262 (P=0.04), and IDI was 0.085 (P=0.01), indicating that the predictive ability of PDW combined with SSIGN model was improved. Conclusion: Preoperative high PLT and low PDW are associated with adverse prognosis of locally advanced renal cell carcinoma, and PDW is an independent risk factor. Therefore, preoperative PDW could serve as biomarker for risk stratification of locally advanced renal cell carcinoma.

Key words: Renal cell carcinoma, Locally advanced, Platelet, Prognosis

中图分类号: 

  • R737.11

表1

患者临床组织病理学资料及与疾病进展相关单因素分析"

Characteristics Progression free
(n=128, 66.7%)		 Progression
(n=64, 33.3%)		 P
Age/years, $\bar{x}±s$ 59.8±12.7 58.6±8.6 0.490
Gender, n(%)
Male 87 (68) 46 (71.9) 0.622
Female 41 (32) 18 (28.1)
Symptom at presentation, n(%) 35 (27.3) 38 (59.4) <0.001*
BMI/(kg/m2), $\bar{x}±s$ 25.4±3.5 24.7±3.3 0.135
Comorbidities, n(%)
Hypertension 54 (42.2) 29 (45.3) 0.758
Diabetes mellitus 26 (20.3) 6 (9.4) 0.065
Surgical approach, n(%)
Open 50 (39.1) 29 (45.3) 0.439
Laparoscopic 78 (60.9) 35 (54.7)
Surgical time/min, $\bar{x}±s$ 193.60±94.03 276.23±130.14 <0.001
Interoperative blood loss/mL, $\bar{x}±s$ 359.53±951.83 711.72±1 063.19 0.027
Tumor side, n(%) 1.000
Left 69 (53.9) 34 (53.1)
Right 59 (46.1) 30 (46.9)
Tumor size/cm, $\bar{x}±s$ 6.6±3.7 7.1±2.8 0.345
Histologic subtype, n(%) 0.649
CCRCC 113 (88.3) 55 (85.9)
Non-CCRCC 15 (11.7) 9 (14.1)
Nuclear grade, n(%) <0.001*
Ⅰ to Ⅱ 86 (67.2) 27 (42.2)
Ⅲ to Ⅳ 32 (25) 36 (56.3)
Unknow 10 (7.8) 1 (1.6)
Necrosis, n(%) 27 (21.1) 33 (51.6) <0.001*
Sarcomatoid differentiation, n(%) 4 (3.1) 7 (10.9) 0.044*
Rheumatoid differentiation, n(%) 5 (3.9) 5 (7.8) 0.305
Lymphovascular invasion, n(%) 14 (10.9) 17 (26.6) 0.011*
Renal sinus invasion, n(%) 95 (74.2) 47 (73.4) 1.000
Perirenal fat invasion, n(%) 30 (23.4) 23 (35.9) 0.087
Urinary collecting system invasion, n(%) 3 (2.3) 5 (7.8) 0.120
Venous tumor thrombus, n(%) 37 (28.9) 38 (59.4) <0.001*
Lymph node invasion, n(%) 2 (1.6) 6 (9.4) 0.018*
Adrenal invasion, n(%) 4 (3.1) 6 (9.4) 0.086
SSIGN score, n(%) 0.013
0-3 46 (35.9) 12 (18.8)
4-6 73 (57) 41 (64.1)
7-11 9 (7) 11 (17.2)
Platelet indices
PLT/(×109/L), $\bar{x}±s$ 227.27±66.94 250.72±88.59 0.042*
MPV/fL, $\bar{x}±s$ 10.12±1.26 9.96±0.97 0.394
PDW/%, $\bar{x}±s$ 13.31±2.74 12.01±2.27 0.001*

图1

Kaplan-Meier法绘制患者在术前不同水平PLT(A)和PDW(B)的肾癌无进展生存曲线"

表2

肾癌术后发生进展Cox比例风险模型多因素分析"

Items B SE Wald P Exp(B) (95%CI)
Nuclear grade
Ⅰ to Ⅱ Ref - - - -
Ⅲ to Ⅳ 0.886 0.275 10.343 0.001 2.425 (1.413-4.161)
Unknow -0.984 1.021 0.929 0.335 0.374 (0.051-2.764)
Sarcomatoid differentiation 1.132 0.428 6.999 0.008 3.101 (1.341-7.170)
PDW* -0.308 0.067 20.884 <0.001 0.735 (0.644-0.839)

图2

时间依赖ROC曲线评估术前PDW联合SSIGN预后评分模型对原有模型改良情况"

[1] Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis [J]. Nat Rev Cancer, 2011, 11(2):123-134.
doi: 10.1038/nrc3004
[2] Labelle M, Begum S, Hynes RO. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis [J]. Cancer Cell, 2011, 20(5):576-590.
doi: 10.1016/j.ccr.2011.09.009 pmid: 22094253
[3] Nieswandt B, Hafner M, Echtenacher B, et al. Lysis of tumor cells by natural killer cells in mice is impeded by platelets [J]. Cancer Res, 1999, 59(6):1295-1300.
pmid: 10096562
[4] Zhu X, Cao Y, Lu P, et al. Evaluation of platelet indices as diagnostic biomarkers for colorectal cancer [J]. Sci Rep, 2018, 8(1):11814.
doi: 10.1038/s41598-018-29293-x
[5] Liu C, Zhang H, Qi Q, et al. The preoperative platelet distribution width: A predictive factor of the prognosis in patients with non-small cell lung cancer [J]. Thorac Cancer, 2020, 11(4):918-927.
doi: 10.1111/tca.v11.4
[6] Liu S, Fang J, Jiao D, et al. Elevated platelet count predicts poor prognosis in breast cancer patients with supraclavicular lymph node metastasis [J]. Cancer Manag Res, 2020, 12(6):6069-6075.
doi: 10.2147/CMAR.S257727
[7] Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study [J]. Lancet Oncol, 2013, 14(2):141-148.
doi: 10.1016/S1470-2045(12)70559-4
[8] Choi JY, Ko YH, Song PH. Clinical significance of preoperative thrombocytosis in patients who underwent radical nephrectomy for nonmetastatic renal cell carcinoma [J]. Investig Clin Urol, 2016, 57(5):324-329.
doi: 10.4111/icu.2016.57.5.324
[9] Seles M, Posch F, Pichler GP, et al. Blood platelet volume represents a novel prognostic factor in patients with nonmetastatic renal cell carcinoma and improves the predictive ability of established prognostic scores [J]. J Urol, 2017, 198(6):1247-1252.
doi: 10.1016/j.juro.2017.07.036
[10] Karakiewicz PI, Trinh QD, Lam JS, et al. Platelet count and preoperative haemoglobin do not significantly increase the performance of established predictors of renal cell carcinoma-specific mortality [J]. Eur Urol, 2007, 52(5):1428-1436.
pmid: 17420085
[11] Frank I, Blute ML, Cheville JC, et al. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score [J]. J Urol, 2002, 168(6):2395-2400.
doi: 10.1016/S0022-5347(05)64153-5
[12] Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system [J]. J Clin Oncol, 2001, 19(6):1649-1657.
pmid: 11250993
[13] Amin MB, Edge SB, Greene FL, et al. AJCC cancer staging manual[M]. 8th ed. Chicago: Springer, 2017: 739-747.
[14] Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update [J]. Eur Urol, 2015, 67(5):913-924.
doi: 10.1016/j.eururo.2015.01.005 pmid: 25616710
[15] Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours [J]. Eur Urol, 2016, 70(1):93-105.
doi: 10.1016/j.eururo.2016.02.029
[16] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021 [J]. CA Cancer J Clin, 2021, 71(1):7-33.
doi: 10.3322/caac.v71.1
[17] Haas NB, Manola J, Dutcher JP, et al. Adjuvant treatment for high-risk clear cell renal cancer: updated results of a high-risk subset of the ASSURE randomized trial [J]. JAMA Oncol, 2017, 3(9):1249-1252.
doi: 10.1001/jamaoncol.2017.0076
[18] Motzer RJ, Haas NB, Donskov F, et al. Randomized phase Ⅲ trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma [J]. J Clin Oncol, 2017, 35(35):3916-3923.
doi: 10.1200/JCO.2017.73.5324
[19] Motzer RJ, Ravaud A, Patard JJ, et al. Adjuvant sunitinib for high-risk renal cell carcinoma after nephrectomy: subgroup analyses and updated overall survival results [J]. Eur Urol, 2018, 73(1):62-68.
doi: 10.1016/j.eururo.2017.09.008
[20] Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials [J]. Cancer, 2003, 97(7):1663-1671.
pmid: 12655523
[21] Karakiewicz PI, Briganti A, Chun FK, et al. Multi-institutional validation of a new renal cancer-specific survival nomogram [J]. J Clin Oncol, 2007, 25(11):1316-1322.
pmid: 17416852
[22] Correa AF, Jegede O, Haas NB, et al. Predicting renal cancer recurrence: defining limitations of existing prognostic models with prospective trial-based validation [J]. J Clin Oncol, 2019, 37(23):2062-2071.
doi: 10.1200/JCO.19.00107
[23] Xiao R, Xu C, He W, et al. Preoperative anaemia and thrombocytosis predict adverse prognosis in non-metastatic renal cell carcinoma with tumour thrombus [J]. BMC Urol, 2021, 21(1):31.
doi: 10.1186/s12894-021-00796-6
[24] Yue CX, Liu YX, Yun ZY, et al. Decreased platelet distribution width predicts a worse prognosis in patients undergoing surgical resection for hepatocellular carcinoma [J]. Cancer Biomark, 2019, 26(3):361-366.
doi: 10.3233/CBM-190474
[25] Chen H, Wu Q, Zhang Y, et al. Nomograms based on the novel platelet index score predict postoperative prognosis in endometrial cancer [J]. Gynecol Oncol, 2020, 158(3):689-697.
doi: S0090-8258(20)31125-2 pmid: 32507649
[26] Kawakita Y, Motoyama S, Sato Y, et al. Prognostic significance of combined platelet distribution width and C-reactive protein score in esophageal cancer [J]. Anticancer Res, 2020, 40(10):5715-5725.
doi: 10.21873/anticanres.14586 pmid: 32988897
[27] 蒋慧云, 李小毛, 王佳, 等. 术前血小板分布宽度在子宫内膜癌诊断预测中的价值 [J]. 实用医学杂志, 2018, 34(7):1188-1190.
[28] Vagdatli E, Gounari E, Lazaridou E, et al. Platelet distribution width: a simple, practical and specific marker of activation of coagulation [J]. Hippokratia, 2010, 14(1):28-32.
pmid: 20411056
[29] 张翔, 庄瑞. 血小板分布宽度对鼻咽癌患者预后的影响 [J]. 国际肿瘤学杂志, 2018, 45(5):257-261.
[30] Huang Y, Cui MM, Huang YX, et al. Preoperative platelet distribution width predicts breast cancer survival [J]. Cancer Biomark, 2018, 23(2):205-211.
doi: 10.3233/CBM-181267 pmid: 30198864
[31] 张林楠, 刘玉峰, 苏淑芳, 等. 血小板分布宽度对神经母细胞瘤预后的预测价值 [J]. 中华实用儿科临床杂志, 2020, 35(6):440-444.
[1] 蓝璘,贺洋,安金刚,张益. 颧骨缺损不同修复重建方法和预后的回顾性分析[J]. 北京大学学报（医学版）, 2022, 54(2): 356-362.
[2] 王飞,朱翔,贺蓓,朱红,沈宁. 自发缓解的滤泡性细支气管炎伴非特异性间质性肺炎1例报道并文献复习[J]. 北京大学学报（医学版）, 2021, 53(6): 1196-1200.
[3] 高伟波,石茂静,张海燕,吴春波,朱继红. 显著高铁蛋白血症与噬血细胞性淋巴组织细胞增多症的相互关系[J]. 北京大学学报（医学版）, 2021, 53(5): 921-927.
[4] 张梅香,史文芝,刘建新,王春键,李燕,王蔚,江滨. MLL-AF6融合基因阳性急性髓系白血病的临床特征及预后[J]. 北京大学学报（医学版）, 2021, 53(5): 915-920.
[5] 蒋艳芳,王健,王永健,刘佳,裴殷,刘晓鹏,敖英芳,马勇. 前交叉韧带翻修重建术后中长期临床疗效及影响因素[J]. 北京大学学报（医学版）, 2021, 53(5): 857-863.
[6] 于妍斐,何世明,吴宇财,熊盛炜,沈棋,李妍妍,杨风,何群,李学松. 延胡索酸水合酶缺陷型肾细胞癌的临床病理特征及预后[J]. 北京大学学报（医学版）, 2021, 53(4): 640-646.
[7] 赵勋,颜野,黄晓娟,董靖晗,刘茁,张洪宪,刘承,马潞林. 癌栓粘连血管壁对非转移性肾细胞癌合并下腔静脉癌栓患者手术及预后的影响[J]. 北京大学学报（医学版）, 2021, 53(4): 665-670.
[8] 洪鹏,田晓军,赵小钰,杨飞龙,刘茁,陆敏,赵磊,马潞林. 肾移植术后双侧乳头状肾癌1例[J]. 北京大学学报（医学版）, 2021, 53(4): 811-813.
[9] 陈怀安,刘硕,李秀君,王哲,张潮,李凤岐,苗文隆. 炎症生物标志物对输尿管尿路上皮癌患者预后预测的临床价值[J]. 北京大学学报（医学版）, 2021, 53(2): 302-307.
[10] 石茂静,高伟波,黄文凤,朱继红. 61例血栓性血小板减少性紫癜患者的临床分析[J]. 北京大学学报（医学版）, 2021, 53(1): 210-214.
[11] 刘世博,高辉,冯元春,李静,张彤,万利,刘燕鹰,李胜光,罗成华,张学武. 腹膜后纤维化致肾盂积水的临床分析:附17例报道[J]. 北京大学学报（医学版）, 2020, 52(6): 1069-1074.
[12] 刘滕飞,林涛,任利辉,李广平,彭建军. CMTM5基因与冠心病患者支架内再狭窄发生风险[J]. 北京大学学报（医学版）, 2020, 52(5): 856-862.
[13] 陈伟钱,戴小娜,余叶,王沁,梁钧昱,柯旖旎,易彩虹,林进. 原发性干燥综合征合并自身免疫性肝病的临床特点及预后分析[J]. 北京大学学报（医学版）, 2020, 52(5): 886-891.
[14] 郭倩, 马晓旭, 高辉, 石连杰, 钟昱超, 谢琳峰, 邵苗, 张学武. Semaphorin 3A在系统性红斑狼疮合并血小板减少患者中的水平及意义[J]. 北京大学学报（医学版）, 2020, 52(5): 892-896.
[15] 郜洪宇,徐菁玲,孟焕新,和璐,侯建霞. 牙周基础治疗对2型糖尿病伴慢性牙周炎患者红细胞、血小板相关指标的影响[J]. 北京大学学报（医学版）, 2020, 52(4): 750-754.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
[1] 张三. 中文标题测试[J]. 北京大学学报（医学版）, 2010, 42(1): 1 -10 .
[2] 赵磊, 王天龙 . 右心室舒张末期容量监测用于肝移植术中容量管理的临床研究[J]. 北京大学学报（医学版）, 2009, 41(2): 188 -191 .
[3] 万有, , 韩济生, John E. Pintar. 孤啡肽基因敲除小鼠电针镇痛作用增强[J]. 北京大学学报（医学版）, 2009, 41(3): 376 -379 .
[4] 张燕, 韩志慧, 钟延丰, 王盛兰, 李玲玲, 郑丹枫. 骨骼肌活组织检查病理诊断技术的改进及应用[J]. 北京大学学报（医学版）, 2009, 41(4): 459 -462 .
[5] 赵奇, 薛世华, 刘志勇, 吴凌云. 同向施压测定自酸蚀与全酸蚀粘接系统粘接强度[J]. 北京大学学报（医学版）, 2010, 42(1): 82 -84 .
[6] 林红, 王玉凤, 吴野平. 学校生活技能教育对小学三年级学生行为问题影响的对照研究[J]. 北京大学学报（医学版）, 2007, 39(3): 319 -322 .
[7] 丰雷, 程嘉, 王玉凤. 注意缺陷多动障碍儿童的运动协调功能[J]. 北京大学学报（医学版）, 2007, 39(3): 333 -336 .
[8] 李岳玲, 钱秋瑾, 王玉凤. 儿童注意缺陷多动障碍成人期预后及其预测因素[J]. 北京大学学报（医学版）, 2007, 39(3): 337 -340 .
[9] . 书讯[J]. 北京大学学报（医学版）, 2007, 39(3): 225 -328 .
[10] 牟向东, 王广发, 刁小莉, 阙呈立. 肺黏膜相关淋巴组织型边缘区B细胞淋巴瘤一例[J]. 北京大学学报（医学版）, 2007, 39(4): 346 -350 .
ISSN 1671-167X
CN 11-4691/R
主管单位：中华人民共和国教育部
主办单位：北京大学
地址： 北京市海淀区学院路38号 北京大学医学部 《北京大学学报（医学版）》
邮编：100191
电话：010-82801551
Email： xbbjb2@bjmu.edu.cn

《北京大学学报（医学版）》
微信公众号
版权所有 © 2018 《北京大学学报（医学版）》编辑部